WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”), (NASDAQ: GEG), today announced plans to host a conference call and webcast to discuss its results for the fiscal quarter ended March 31, 2023, on Friday, May 5, 2023, at 9:00 a.m., ET.
Company to Host Conference Call & Webcast
Great Elm will host a conference call and webcast on Friday, May 5, 2023, at 9:00 a.m. Eastern Time to discuss its fiscal 2023 third quarter financial results.
All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked.
For a copy of the slide presentation that will be referenced during the conference call, please visit: https://www.greatelmgroup.com/events-and-presentations.
The conference call will be webcast simultaneously and can be accessed at the following link: https://events.q4inc.com/attendee/141685606.
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.03 |
Daily Change: | -0.06 -2.87 |
Daily Volume: | 1,030 |
Market Cap: | US$59.380M |
February 05, 2025 November 11, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load